Smarter drug trials can get new meds to the right patients
Startup uses AI to improve the design, execution and analysis of clinical trials, the longest and costliest part of drug development that often fails.
Startup uses AI to improve the design, execution and analysis of clinical trials, the longest and costliest part of drug development that often fails.
Suicidal bipolar depression accounts for 40% of people who try to harm themselves, yet there’s never been an FDA-approved drug for this indication.
Prof. Roger D. Kornberg, Chemistry Nobel laureate, will be joining Tissue Dynamics’ advisory board.
Neuromagen Pharma secures funding to test a new class of small molecules to treat amyotrophic lateral sclerosis and other neurodegenerative diseases.
‘Covid-19 and the various viral mutations will likely be with us for a long time and thus effective treatment is key,’ says Pepticom CEO.
‘We are now able to insert microsensors that offer us real-time information on how drugs work and when they stop working.’
‘Instead of having to check millions of molecules, we may check just 20, 100 or maybe up to 3,000 molecules,’ says Jerusalem-based Pepticom.
New method will shorten the wait for novel drugs, and can lead to development of drugs that would not have been generated by existing methods.